Alembic Pharmaceuticals Limited (APLLTD.NS)
INR 846.4
(0.73%)
INR 846.4
(0.73%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.86 Billion INR | -40.21% |
| 2022 | 6.46 Billion INR | -1.45% |
| 2021 | 6.56 Billion INR | 35.11% |
| 2020 | 4.85 Billion INR | -72.39% |
| 2019 | 17.58 Billion INR | 89.25% |
| 2018 | 9.29 Billion INR | 48.93% |
| 2017 | 6.24 Billion INR | 1066.59% |
| 2016 | -645.6 Million INR | 78.07% |
| 2015 | -2.94 Billion INR | -224.4% |
| 2014 | 2.36 Billion INR | 177.02% |
| 2013 | 854.36 Million INR | -49.95% |
| 2012 | 1.7 Billion INR | -8.84% |
| 2011 | 1.87 Billion INR | -41.78% |
| 2010 | 3.21 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 754.8 Million INR | -88.33% |
| 2023 Q3 | 1.47 Billion INR | -79.68% |
| 2023 Q2 | 7.27 Billion INR | 863.79% |
| 2023 Q4 | 3.86 Billion INR | 161.56% |
| 2023 FY | 3.86 Billion INR | -40.21% |
| 2022 Q3 | 722.2 Million INR | -89.76% |
| 2022 FY | 6.46 Billion INR | -1.45% |
| 2022 Q1 | 694.3 Million INR | -89.42% |
| 2022 Q2 | 7.05 Billion INR | 915.76% |
| 2022 Q4 | 6.46 Billion INR | 795.24% |
| 2021 Q4 | 6.56 Billion INR | 95.55% |
| 2021 FY | 6.56 Billion INR | 35.11% |
| 2021 Q2 | 8.15 Billion INR | 186.25% |
| 2021 Q1 | 2.85 Billion INR | -41.3% |
| 2021 Q3 | 3.35 Billion INR | -58.88% |
| 2020 Q4 | 4.85 Billion INR | 72.96% |
| 2020 Q3 | 2.8 Billion INR | -14.24% |
| 2020 Q2 | 3.27 Billion INR | 355.67% |
| 2020 Q1 | 718.4 Million INR | -95.92% |
| 2020 FY | 4.85 Billion INR | -72.39% |
| 2019 FY | 17.58 Billion INR | 89.25% |
| 2019 Q2 | 12.35 Billion INR | 520.83% |
| 2019 Q3 | 893.9 Million INR | -92.77% |
| 2019 Q4 | 17.58 Billion INR | 1867.61% |
| 2019 Q1 | 1.99 Billion INR | -78.58% |
| 2018 Q2 | 10.15 Billion INR | 1112.17% |
| 2018 Q3 | 873.3 Million INR | -91.4% |
| 2018 Q4 | 9.29 Billion INR | 964.19% |
| 2018 FY | 9.29 Billion INR | 48.93% |
| 2018 Q1 | 837.4 Million INR | -86.58% |
| 2017 FY | 6.24 Billion INR | 1066.59% |
| 2017 Q4 | 6.24 Billion INR | 270.23% |
| 2017 Q3 | 1.68 Billion INR | -20.53% |
| 2017 Q2 | 2.12 Billion INR | 22.09% |
| 2017 Q1 | 1.73 Billion INR | 369.07% |
| 2016 Q4 | -645.6 Million INR | -118.76% |
| 2016 Q2 | -1.99 Billion INR | -144.26% |
| 2016 FY | -645.6 Million INR | 78.07% |
| 2016 Q1 | 4.5 Billion INR | 253.13% |
| 2016 Q3 | 3.44 Billion INR | 272.5% |
| 2015 Q3 | 2.11 Billion INR | 1173.17% |
| 2015 Q4 | -2.94 Billion INR | -239.4% |
| 2015 Q2 | -196.8 Million INR | -173.36% |
| 2015 Q1 | 268.25 Million INR | -88.67% |
| 2015 FY | -2.94 Billion INR | -224.4% |
| 2014 Q3 | 525.6 Million INR | -65.19% |
| 2014 Q2 | 1.51 Billion INR | 530.22% |
| 2014 Q1 | 239.61 Million INR | -71.95% |
| 2014 FY | 2.36 Billion INR | 177.02% |
| 2014 Q4 | 2.36 Billion INR | 350.29% |
| 2013 FY | 854.36 Million INR | -49.95% |
| 2013 Q4 | 854.36 Million INR | 873.08% |
| 2013 Q3 | 87.8 Million INR | -94.04% |
| 2013 Q2 | 1.47 Billion INR | 814.88% |
| 2013 Q1 | 161.06 Million INR | -90.56% |
| 2012 Q4 | 1.7 Billion INR | 0.0% |
| 2012 FY | 1.7 Billion INR | -8.84% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 1.08 Billion INR | 0.0% |
| 2011 FY | 1.87 Billion INR | -41.78% |
| 2010 FY | 3.21 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Hester Biosciences Limited | 2.29 Billion INR | -68.762% |
| Aarti Drugs Limited | 5.54 Billion INR | 30.324% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -48.011% |
| Albert David Limited | -278.36 Million INR | 1488.768% |
| Alembic Limited | 66.9 Million INR | -5678.625% |
| Alkem Laboratories Limited | -1.6 Billion INR | 340.208% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -1581.316% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -17.186% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 21057.931% |
| Brooks Laboratories Limited | 49.48 Million INR | -7712.266% |
| Eris Lifesciences Limited | 13.8 Billion INR | 71.999% |
| FDC Limited | -57.75 Million INR | 6793.967% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 235.996% |
| Gufic Biosciences Limited | 3.19 Billion INR | -21.024% |
| Hikal Limited | 7.96 Billion INR | 51.476% |
| Ind-Swift Limited | 9.5 Billion INR | 59.343% |
| Innova Captab Limited | 2.33 Billion INR | -65.651% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 451.031% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 378.136% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 85.72% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 3128.8% |
| Lupin Limited | 19.38 Billion INR | 80.057% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -296.173% |
| Medico Remedies Limited | 78.67 Million INR | -4813.634% |
| Morepen Laboratories Limited | -231.17 Million INR | 1772.29% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 37.214% |
| Orchid Pharma Limited | -1.31 Billion INR | 394.243% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 264.647% |
| RPG Life Sciences Limited | -364.7 Million INR | 1160.022% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -3120.537% |
| Sigachi Industries Limited | 859.94 Million INR | -349.55% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 61.464% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -2566.579% |
| Themis Medicare Limited | 764.96 Million INR | -405.372% |
| Unichem Laboratories Limited | 931.91 Million INR | -314.834% |
| Vaishali Pharma Limited | 119.13 Million INR | -3144.974% |
| Wanbury Limited | 1.1 Billion INR | -249.578% |
| Windlas Biotech Limited | -273.04 Million INR | 1515.873% |
| ZIM Laboratories Limited | 983.6 Million INR | -293.034% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 193.086% |
| Ipca Laboratories Limited | 11.41 Billion INR | 66.134% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 105.334% |
| Venus Remedies Limited | -267.7 Million INR | 1544.117% |
| Sakar Healthcare Limited | 790.93 Million INR | -388.775% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -4.673% |
| Divi's Laboratories Limited | -39.77 Billion INR | 109.721% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 177.126% |
| Mankind Pharma Limited | -1.74 Billion INR | 321.117% |
| Sequent Scientific Limited | 4.17 Billion INR | 7.484% |
| Laurus Labs Limited | 24.35 Billion INR | 84.129% |
| Neuland Laboratories Limited | -214.05 Million INR | 1906.006% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -37.03% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 190.214% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 1.178% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1653.868% |
| Wockhardt Limited | 18.27 Billion INR | 78.84% |
| Bal Pharma Limited | 1.26 Billion INR | -205.953% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 70.062% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 433.914% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 1154.704% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 170.191% |
| Shilpa Medicare Limited | 9.06 Billion INR | 57.375% |
| Valiant Laboratories Limited | 649.9 Million INR | -494.844% |
| Ajanta Pharma Limited | -954.9 Million INR | 504.849% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -1199.116% |
| Granules India Limited | 9.28 Billion INR | 58.372% |
| Medicamen Biotech Limited | 160.31 Million INR | -2311.425% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -8265.757% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.213% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 87.855% |
| NATCO Pharma Limited | -5.81 Billion INR | 166.459% |
| Suven Life Sciences Limited | -1.63 Billion INR | 336.78% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -100.003% |
| Strides Pharma Science Limited | 23.25 Billion INR | 83.377% |
| Indoco Remedies Limited | 6.47 Billion INR | 40.307% |
| Alpa Laboratories Limited | 35.36 Million INR | -10832.048% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1778.483% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 510.48% |